Paul F. Malloy Professor of Psychiatry and Human Behavior

Dr. Malloy graduated from Dartmouth College in 1972, and served as a Navy officer for the next four years. He earned a PhD in clinical psychology from SUNY Binghamton in 1981. He has been on the Brown Faculty since 1983. He serves as Director of Psychology and Co-Director of the Memory and Aging Program at Butler Hospital. He coordinated the Neuropsychology Track of the Brown Clinical Psychology Training Consortium for many years, and is now Associate Director of the Psychology Division of the DPHB.

Brown Affiliations

Research Areas

scholarly work

Malloy, P.F., Correia, S., Stebbins, G., & Laidlaw, D. (2007). Neuroimaging of white matter in aging and dementia. The Clinical Neuropsychologist, 21, 1-38.

Malloy, P.F., Tremont, G., Grace, J., & Frakey, L. The Frontal Systems Behavior Scale (FrSBe) discriminates frontotemporal dementia from Alzheimer's disease. Alzheimer's and Related Disorders: Journal of the Alzheimer's Association.

Malloy, P.F. & Grace, J. (2005). A review of rating scales for measuring behavior change due to frontal systems damage. Cognitive and Behavioral Neurology, 18, 18-27.

Grace, J. & Malloy, P.F. (2002). The Frontal Systems Behavior Scale (FrSBe). Psychological Assessment Resources, Odessa, FL.

Salloway S, Malloy P, Duffy J. (2001). The frontal lobes and neuropsychiatric illness. American Psychiatric Press Inc., Washington, D.C.

Malloy, P.F., & Aloia, M. (1998). Frontal lobe dysfunction in traumatic brain injury. Seminars in Clinical Neuropsychiatry, 3, 186-194.

Malloy, P.F. & Duffy, J. (1994). The frontal lobes in neuropsychiatric disorder. In F. Boller & J. Grafman (Eds.), Handbook of Neuropsychology (Vol. 9), 203-232.

Malloy, P.F. & Richardson, E.D. (1994). The frontal lobes and content-specific delusions. Journal of Neuropsychiatry and Clinical Neuroscience, 6, 455-466.

Malloy, P. F., Rasmussen, S., Braden, W. and Haier, R. (1989). Topographic evoked potential mapping in obsessive-compulsive disorder: Evidence of frontal lobe dysfunction. Psychiatry Research, 28, 63-71.

research overview

Paul Malloy's primary research interest is frontal lobe/executive functions in neuropsychiatric disorders, with a current focus on dementia. He is investigating the role of small vessel cerebrovascular disease in causing executive deficits using behavioral and neuroimaging techniques. In addition, a series of projects have demonstrated the relationship between executive problems and poor outcomes such as increased caregiver burden, failure in activities of daily living, and apathy. He is also involved in studies measuring executive functioning in obsessive-compulsive disorder (OCD) and depression in patients undergoing deep brain stimulation treatment.

research statement

My research focuses on the functions of the frontal lobes of the brain in normal behavior and in disease. Toward that end, my colleagues and I have conducted research on a wide variety of populations, ranging from normal elderly to patients with brain lesions. Among the topics we have studied in recent years are:

- The relationship between executive problems and activities of daily living in the elderly;
- Measurement of non-cognitive behavior change in dementia;
- The role of frontal dysfunction in obsessive-compulsive disorder (OCD).

Methodological efforts have included the development of the Frontal Systems Behavior Scale (FrSBe) (designed to measure dysexecutive, disinhibited, and apathetic changes in behavior after brain injury) and analysis of MRI scans to measure small-vessel cerebrovascular disease.

funded research

1983-1988 Co-investigator, Environmental treatment of alcohol abusers.

(National Institute on Alcohol Abuse and Alcoholism (NIAAA)-AA05827-01A. $677,258).

 

1983-1988 Co-investigator, Prediction of treatment outcome in alcoholism using neuropsychological tests.

(NIAAA-AA06698-01. $38,966).

 

1985 Co-investigator, Treatment of memory deficits in Korsakoff's patients with guanfacine.

(A. H. Robins Pharmaceuticals. $92,750).

 

1988-1989 Co-investigator, Environmental treatment of alcohol abusers, competitive renewal.

(NIAAA-AA06698-04. $137,756).

 

1989-1992 Co-investigator, Treatment of primary degenerative dementia with nimodopine.

(Miles Laboratories. $440,000).

 

1993-1995 Principal Investigator. Multicenter comparison of placebo and Mentane in outpatients with Alzheimer's disease.

(Hoechst Celenase Corp.)

 

1994-1995 Principal Investigator. Development of a computerized teaching program in neuroimaging.

(Wayland Collegium, Brown University... $2500).

 

1993-1995 Principal Investigator. Quantitative MRI analysis of subcortical white matter changes in late-life onset depression.

(Brown University Department of Psychiatry and Human Behavior. $46,000).

 

1997-1998 Co-investigator. An eight-week, parallel group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. (Pfizer Pharmaceuticals R-0552).

 

1997-2001 Principal Investigator. Relationship of MRI hyperintensities to treatment response in geriatric depression.

(Pfizer Pharmaceuticals R-0552. $50,000).

 

1997-2002 Co-investigator. Attentional and cognitive training in vital community elderly (ACTIVE).

(National Institute on Aging (NIA) 5U101 NR4507-03).

 

1998-2001 Co-investigator. A multi-center evaluation of the efficacy and safety of donepezil hydrochloride in patients with dementia associated with cerebrovascular disease.

(Eisai Inc. E2020-A0001-307).

 

1998-2000 Principal Investigator. A multicenter evaluation of the efficacy and safety of donepezil hydrochloride (E2020) in subjects with mild cognitive impairment.

(Eisai/Pfizer E2020-A001-401).

 

1999-2004 Co- investigator; PI: R. Cohen. Heart disease, CNS dysfunction, and outcome in the elderly.

(National Institutes of Health (NIH)-NIA RO1 1999-PRG-1837)

 

2000-2001 Co-investigator; PI: D. Cahn-Weiner. Combined Pharmacologic and Behavioral Intervention to Improve Memory in Alzheimer's Disease

(Alzheimer's Association).

 

2000-2001 Co-investigator. Relationship of MRI hyperintensities to treatment response in geriatric depression.

(PI: R. Krishnan; Pfizer Pharmaceuticals R-0552).

 

2000-2002 Co-investigator; M. Aloia, PI. Improving sleep and cognitive functioning in Alzheimer's Disease.

(Pfizer Pharmaceuticals, investigator-initiated).

 

2000-2001 Co-Investigator. A randomized double blind placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment (MCI) clinically at risk for development of clinically probable Alzheimer's Disease.

(Jannsen Research Foundation GAL-INT-11).

 

2000-2004 Co-Principal Investigator, Butler site; PI: M. Sano. Alzheimer's disease prevention trial with estrogens.

(NIA)

 

2001-2003 Co-Principal Investigator; Co-PI: Patricia Boyle. Pharmacologic vs. combined pharmacologic-behavioral treatment for apathy in Alzheimer's disease.

(Alzheimer's Association, NIRG-01-2686).

 

2001-2002 Co-investigator. A double-blind, randomized pilot study to evaluate the effects of galantamine and donepezil on sleep and attention and GI tolerance in patients with mild to moderate Alzheimer's disease.

(Janssen Research Foundation, GAL-USA-24).

 

2002-2003 Co-Investigator. A 12-week, double-blind study in patients with mild to moderate Alzheimer's disease who either continue ongoing Donepezil therapy or switch to Galantamine Hydrobromide.

(Eisai Inc., E2020-A001-411).

 

2002-2003 Co-Investigator; PI-John Morris. Cognitive approach to maintaining self-care involvement.

(NIA 3 U01 NR04507-0582).

 

2003 Co-Principal Investigator. A randomized, double-blind, placebo-controlled study of C105 (levo-amphetamine sulfate) to improve memory in patients suffering from anterior communicating aneurysm syndrome.

(Sention, Inc. 22013. $22,552).

 

2003-2004 Co-Principal Investigator. A randomized, double-blind, placebo-controlled study of C105 to improve memory in patients suffering from mild cognitive impairment.

(Sention, Inc. 22020. $157,400).

 

2003 Co-Investigator. A Phase II Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Multicenter, Safety and Efficacy Evaluation of Three Doses of NS 2330 in Patients with Mild to Moderate Dementia of the Alzheimer's Type.

(Boehringer Ingelheim Pharmaceuticals, Inc #1198.052. $51,020).

 

2003-2004 Co-Principal Investigator. A 24-week, multi-centered, randomized, double-blind, placebo-controlled evaluation of the efficacy, safety and tolerability of donepezil hydrochloride (E2020) in patients with dementia associated with cerebrovascular disease.

(Eisai Medical Research, Inc. # E2020-A001-319. $132,820)

 

2003-2004 Co-Principal Investigator. An 80-week, randomized, multi-center, parallel-group, double-blind study of the efficacy and safety of atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhibitor alone in the treatment of mild to moderate Alzheimer's disease.

(Pfizer, Inc #A2581078. $274,240).

 

2003-2005 Co-Investigator; PI: S. Correia, Working memory and frontal white matter integrity in mild cognitive impairment.

(Alzheimer's Association.).

 

2003-2008 Principal Investigator. Brown Dementia Research Fellowship.

(NIA #T32 AG0200498-01A1. $1,135,000).

 

2004- Co-Investigator. A 1-year, multicenter, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of Donepezil Hyudrochloride (E2020) in subjects with mild cognitive impairment.

(Eisai # E2020-A001-412).

 

2004- Co-investigator. Galantamine ER open label rapid dose escalation trial in Alzheimer's disease.

(Janssen Pharmaceutica #GAL-ALZ-303. $32,000)

 

2004- Co-investigator. A double-blind, phase II, safety and efficacy evaluation of ONO-2506PO in patients with mild to moderate Alzheimer's disease.

(Ono Pharmaceutical Co. ONO-2506POU010. $214,890).

 

2004- Co-Investigator. A phase III study of the efficacy and safety of Alzhemed™ in patients in mild to moderate Alzheimer's disease

(Neurochem #CL-758007. $231,000).

 

2004- Co-Investigator. An open-label eight week investigation of the safety and efficacy of escitalopram for the treatment of anxiety and depression in dementia caregivers.

(Forest Laboratories).

 

2005- Co-investigator; PI: D. Laidlaw. Metrics for qualifying white matter: Image analysis, testing, and application.

(Brown intramural Office of Research award. $100,000).

 

2006- Principal Investigator. Treatment of apathy in Alzheimer's disease with Modafinil. Investigator initiated study.

(Cephalon Pharmaceuticals. $40,000).2006- 2011 Advisory Board, Development of a neuropsychological battery to measure executive dysfunction. (NINDS 05-02, Joel Kramer, PI).

2008- 2009 Co-investigator. A Phase 2 multicenter, randomized, double-blind, placebo-controlled study of the safety, tolerability, and pharmacokinetics of multiple intravenouse doses of PF-04360365 in patients with mild to moderate Alzheimer’s disease. (Pfizer A9951002).

2008- 2010 Co-investigator. A Phase III multicenter, randomized, double-blind, placebo-controlled parallel group, efficacy and safety trial of Bapineuzumab (AAB-001) in patients with mild to moderate Alzheimer’s disease who are apolipoprotein E e4 carriers. (Elan 115727).

2008- 2010 Co-investigator. A Phase III multicenter, randomized, double-blind, placebo-controlled parallel group, efficacy and safety trial of Bapineuzumab (AAB-001) in patients with mild to moderate Alzheimer’s disease who are apolipoprotein E e4 non-carriers. (Elan 115727).

2008- 2010 Co-investigator. A randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study of oral ELND005 (AZD-103) in Alzheimer’s disease. (Elan D005-AD201).

2009- 2012 Principal investigator. CONCERT: A phase-3 multicenter, randomized, placebo-controlled double blind study of Dimebon in patients with mild-to-moderate Alzheimer’s disease on donepezil. (Medivation DIM18).

2007-          Co-investigator. Alzheimer Disease Neuroimaging Initiative (ADNI, ADNI-GO, ADNI-2). (National Institute of Aging; Mark Weiner, PI).

2010-          Co-investigator. Imaging Myelin Loss Associated with Alzheimer's Disease. (Alzheimer's Association; Sean Deoni, PI).

2012-          Co-investigator. A randomized, double-blind, placebo-controlled multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of BIIB037 in subjects with prodromal or mild Alzheimer’s disease. (Biogen 221AD103).

2012-          Co-principal investigator. Amyloid imaging in normal pressure hydrocephalus. (AVID 14-A18).

2012-          Co-investigator. A 12-month double blind, randomized, controlled feasibility study to evaluate the safety, efficacy and tolerability of deep brain stimulation of the fornix (DBS-f) in patients with mild probable Alzheimer’s disease. (ADVANCE; Functional Neuromodulation DBS-FNMI-001)